Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

ClinicalTrials.gov ID: NCT07516132

Public ClinicalTrials.gov record NCT07516132. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3b, Multicenter, Open-Label, Extension Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Study identification

NCT ID
NCT07516132
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Enrollment
850 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 26, 2026
Primary completion
Jul 31, 2030
Completion
Jul 31, 2030
Last update posted
Jun 30, 2026

2026 – 2030

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
California Retina Consultants (CRC) Bakersfield California 93309 Recruiting
California Retina Consultants (CRC) Santa Barbara California 93103 Recruiting
Retina Group of New England Waterford Connecticut 06385 Recruiting
Retina Group of Florida - Fort Lauderdale Fort Lauderdale Florida 33308 Recruiting
Cumberland Valley Retina Associates Hagerstown Maryland 21740 Recruiting
Mid Atlantic Retina Specialists Hagerstown Maryland 21740 Recruiting
Palmetto Retina Center West Columbia South Carolina 29619 Recruiting
Austin Retina Associates Austin Texas 78705 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07516132, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 30, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07516132 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →